Prediction of drug-drug interaction (DDI) between cilostazol and substrates or inhibitors of CYP 2C19 and 3A4

Prediction of drug-drug interaction (DDI) between cilostazol and substrates or inhibitors of CYP 2C19 and 3A4

Software: GastroPlus®
Division: PBPK

The aim of this study was to validate the utility of physiologically based pharamcokinetic (PBPK) models fore predictioin of DDI between cilostazol, kectoconazole, omeprazole and quindine. 

General Approach to Calculation of Tissue:Plasma Partition Coefficients for Physiologically Based Pharmacokinetic (PBPK) Modeling

General Approach to Calculation of Tissue:Plasma Partition Coefficients for Physiologically Based Pharmacokinetic (PBPK) Modeling

Conference: AAPS
Software: GastroPlus®
Division: PBPK

To conduct a comprehensive evaluation of methods for calculation of tissue/plasma partition coefficients with a focus on correct prediction of volume of distribution and recommendation for a general…

Role of Fraction Unbound in Plasma in Calculations of Tissue:Plasma Partition Coefficients

Role of Fraction Unbound in Plasma in Calculations of Tissue:Plasma Partition Coefficients

Conference: AAPS
Division: PBPK

Previous investigations have shown that the Rodgers and Rowland method [Rodgers 2007] for prediction of tissue:plasma partition coefficients (Kps) provides good prediction for compounds with low to moderate…

Level A IVIVC Using a Comprehensive Absorption/PBPK Model for Metoprolol

Level A IVIVC Using a Comprehensive Absorption/PBPK Model for Metoprolol

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Wagner-Nelson,  Loo-Riegelman,  numerical  deconvolution,  and  convolution-based  methods  are conventional ways to form an in vitro-in vivo correlation (IVIVC). The ultimate goal for forming an IVIVC is to…

Modeling Effects of Exenatide on the Pharmacokinetics of Acetaminophen, Digoxin, and Warfarin

Modeling Effects of Exenatide on the Pharmacokinetics of Acetaminophen, Digoxin, and Warfarin

Conference: AAPS

Exenatide, a 39-amino acid peptide used for treatment of type 2 diabetes, is known to inhibit gastric emptying and as a result to alter the absorption of orally administered concomitant medications.

Mechanistic Modeling of Metoprolol Absorption and Pharmacokinetics from Immediate and Modified Release Formulations

Mechanistic Modeling of Metoprolol Absorption and Pharmacokinetics from Immediate and Modified Release Formulations

Conference: CRS
Software: GastroPlus®
Division: PBPK

As one of the most widely used b-blocking agents, metoprolol is also a popular drug in research studies. A number of published studies describe the pharmacokinetics as well as the pharmacodynamics of…

Simulation of Gabapentin Absorption and Bioavailability in Pediatric Patients

Simulation of Gabapentin Absorption and Bioavailability in Pediatric Patients

Conference: ISSX
Division: PBPK

To fit an absorption-pharmacokinetic model for simulation of Gabapentin in adult and pediatric populations. The model will be able to describe the nonlinear dose dependence of absorption mediated by an amino…

Population Pharmacokinetics of Bendamustine and Metabolites in Patients With Indolent Non-Hodgkin Lymphoma

Population Pharmacokinetics of Bendamustine and Metabolites in Patients With Indolent Non-Hodgkin Lymphoma

Conference: ASCPT

Bendamustine is a bifunctional alkylating agent in development as monotherapy and in combination with other agents in the treatment of indolent non-Hodgkin lymphoma (NHL).

Model Feasibility Assessment as a Driver for Model-Based Drug Development

Model Feasibility Assessment as a Driver for Model-Based Drug Development

Conference: ASCPT

Complex pharmacometric analyses raise concerns about cost, time, and reliability of the modelbuilding process (MBP). The goal was to use a model feasibility assessment (MFA) process to improve the performance…

Influence Of Estimation Of Inter-Occasion Variability On Detection Of Time-Varying Covariates

Influence Of Estimation Of Inter-Occasion Variability On Detection Of Time-Varying Covariates

Conference: AAPS

To explore the influence of the estimation of inter-occasion variability (IOV) on the ability to detect time-varying covariates influencing PK parameters from a population PK (PPK) analysis using NONMEM.

Plasma Pharmacokinetic (PK) Profile of Two Consecutive Doses of Ferumoxytol in Healthy Subjects

Plasma Pharmacokinetic (PK) Profile of Two Consecutive Doses of Ferumoxytol in Healthy Subjects

Conference: American Society of Nephrology (ASN)

Ferumoxytol is a carbohydrate-coated superparamagnetic iron oxide nanoparticle being evaluated for safety and efficacy in two distinct areas of medical need.

Effect of Formulation on Adinazolam Pharmacokinetics and Pharmacodynamics

Effect of Formulation on Adinazolam Pharmacokinetics and Pharmacodynamics

Conference: CRS
Division: PBPK

Adinazolam has been reported to have anxiolytic and antidepressant properties [1]. Numerous pharmacokinetic (PK) and pharmacodynamic (PD) studies of immediate release as well as sustained release…

Designing In Vitro Dissolution Tests to Better Mimic In Vivo Release

Designing In Vitro Dissolution Tests to Better Mimic In Vivo Release

Conference: CRS
Division: PBPK

In vitro dissolution tests were traditionally designed for quality control. USP methods commonly used to evaluate the release rate of new controlled release dosage forms are often based on such experiments.

The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process

The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process

Authors: Grasela TH
Conference: PAGE

The current implementation of a pharmacometric process has, in most cases, grown from the ad hoc application of modeling and simulation activities to the drug-development process. This ad hoc…

Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling

Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling

Conference: ASCPT

Successful clinical development of anti-obesity agents is aided by characterization of the placebo effect, which can be significant when lifestyle intervention (LSI) accompanies pharmacologic therapy.

Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide

Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide

Conference: ASCPT

Population pharmacokinetic (PK) and pharmacodynamic (PK/PD) models based on early Phases 1 and 2 data for the new antidiabetic medication exenatide (ex) supported transition from weight-based to…